Start—
and stay
a step ahead
of bladder
cancer.
Our
Test
Bladder Cancer Minimum
Residual Disease (MRD)
from urine DNA
Our
Science
Leveraging the power
of next-generation
sequencing
Clinical
Expertise
Robust clinical
data and large
observational cohorts
We are changing the timeline for cancer detection. Convergent Genomics is on a mission to simplify and accelerate cancer diagnostics serving clinicians and patients with personalized data and actionable insights. Armed with advances in liquid biopsy and next-generation sequencing, we extract DNA from urine to spot cancer risks at a genetic level earlier.
Not just
another test –
a whole new perspective.
When it comes to cancer, we often find ourselves on the back foot – treating, not predicting, and reacting, not acting. UroAmp is a non-invasive genomic urine test that can reveal cancer with great accuracy well before it can be seen with historical standards of care – changing the timeline for cancer recurrence detection.
UroAmp MRD Report
“UroAmp can potentially change how we identify and manage bladder cancer. This breakthrough technology has integrated easily into my practice and provides prognostic and predictive data that is real, repeatable, and quantifiable. It has identified many high-grade and low-grade tumors which cytology missed. The genomic insights are reassuring and helpful in guiding my treatment choices. UroAmp represents an important and much-needed advancement in urothelial cancer care.”
Justin Cohen, MD
There’s a better
way to diagnose
bladder cancer –
earlier and more comprehensively.
We are a genomic diagnostic company founded by a team of cancer biologists, urologic oncologists, and data scientists who came together to advance cancer care and improve outcomes by developing a simple and non-invasive way to reliably detect, monitor, and predict the risk of urothelial cancer from urine.
Learn about
our team
company’s history